



Press release 2007-03-27

Unique results for cancer drug presented in Cambridge

Results from a Swedish study shows that two thirds of the dogs that took part in the research recovered. The unique results were presented in Cambridge on Sunday.

The study was performed by the pharmaceutical company Oasmia Pharmaceutical in co-operation with the Swedish University of Agricultural Studies in Uppsala. It is the first successful study using the cancer drug paclitaxel in dogs. Earlier attempts published have failed because of severe side-effects.

The new pharmaceutical Paclical[®] Vet containing paclitaxel is given as an infusion for 15 minutes every third week until the tumour decreased significantly in size or vanished completely.

- It really is astonishing results that has exceeded all my expectations, says veterinarian Patricio Rivera who has worked with the dogs at the Department of Clinical Sciences at SLU.

The results from the study was presented at the annual veterinary oncological conference in Cambridge, England, shows that earlier incurable tumour diseases in dogs can now be treated. The interest among the participating veterinarians was great.

The company Oasmia and CEO Julian Aleksov counts on a big impact among veterinarians world-wide. The results improve the company's product portfolio, especially the pharmaceutical Paclical[®] for human use.

- We expect that Paclical[®] Vet will be registered during 2008 as the first veterinary cancer drug in the world, Aleksov says.

There are over 140 million dogs in the EU and USA. Approximately 50% of all dogs older than 6 years develop cancer in some form.

Oasmia Pharmaceutical is a pharmaceutical company that specialises in the treatment of severe diseases. Oasmia develops pharmaceuticals for the future.

A pharmaceutical company based on the latest concepts in bio-organic chemistry.

The main idea is to improve the treatment of serious diseases. Primarily, this development is in oncology and treatment with cytostatics but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to whole new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase.

Oasmia is noted on NGM Nordic MTF.

More information is available at www.ngm.se or www.oasmia.com.

For further information contact info@oasmia.com or call +46 18 50 54 40.